Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, has updated ...

How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.

Akeega – which combines the active ingredients in J&J's PARP inhibitor Zejula (niraparib) and androgen blocker Zytiga ...

Men’s Health Month 2025 encourages men to adopt preventive care and healthy lifestyle habits to improve overall health ...

Darolutamide (Nubeqa) is granted FDA approval for metastatic castration-sensitive prostate cancer, enhancing survival and ...

The longtime "SportsCenter" host plans to undergo surgery and is hoping to "normalize" the conversation about the illness.

Johnson & Johnson has reported data from a Phase I trial of pasritamig for metastatic castration-resistant prostate cancer ...

The latest results, which J&J shared at the 2025 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this ...

Acupuncture may reduce nocturia in patients treated for prostate cancer, according to a research letter published online May ...

A multiomic approach for detecting clinically significant prostate cancer in seminal fluid: Results from a large multicenter clinical study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Dr. Cheryl Matter shares expert insights into the role physician education can play in ensuring innovative tools reach patients and help improve patient care.

An AI test boosts cure chances for prostate cancer by predicting who benefits from abiraterone, reducing side effects and ...